148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). (December 2022) - Zhang, J.; Hussein, M.; Kao, S.C-H.; Clay, T.D.; Singhal, N.; Kim, H.R.; Cho, E.K.; Shim, B.; Lee, Y.; Lee, G-W.; Zhao, J.; Yu, Y.; et al.